Drug development. Medical marijuana. Female diagnostics and treatments. These high-growth industries and sectors are the focal points of Easton Pharmaceuticals, Inc.’s (OTC: EAPH) operations. A diversified and specialty company based in Canada, Easton’s operation spans multiple pharmaceutical sectors and other emergent industries, including the medical marijuana market.
In its day-to-day operations, the company balances three mission goals:
It develops and acquires drugs, diagnostics and treatment products that build shareholder value.
It delivers safe, effective and proven products that improve the health and well-being of men and women across global jurisdictions.
It builds and capitalizes on fast-growing and promising industries and sectors defined by products like medical marijuana, vaporizers, e-liquids and other items.
Within the pharmaceutical sector, Easton designs, develops and markets a variety of topical drugs and therapeutic health care products. It formerly developed and owned a wound-healing drug approved the U.S. Food and Drug Administration. Presently, however, its portfolio includes products in various stages of development and approval, from topically-delivered drugs that treat cancer to therapeutic products that treat varied conditions. For one, Easton is the midst of developing XILIVE, an early stage cancer drug. For another, it is growing its product portfolio, which currently includes: Kenestrin Gel used for arthritic pain and pain in the back, elbows, knees, shoulders and wrist; Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Viorra, a hormone-free, non-toxic, and topical gel that improves a woman’s sexual functioning; and a female sexual arousal disorder drug.
Another key product in Easton’s portfolio is AL-Sense (AmnioSense), an amniotic fluid diagnostic leak test. Through a strategic partnership, Easton and another company, BMV Medica SA de C.V., own the exclusive distribution rights for AL-Sense (AmnioSense) in Mexico and Latin America. AL-Sense (AmnioSense) is a patented women’s diagnostic product that has been approved in Europe and is already being sold in the United Kingdom. With the birth rate in Latin America estimated at three times that of North America and most of Europe, it opens up a vast market for the Easton / BMV partnership, one with a population greater than 200 million people. The higher birthrate in the region and other factors also portend a faster rate of sale for pharmaceutical and diagnostic products, approximately five times the rate of North American and European sales.
For more information, visit www.EastonPharmaceuticalsInc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment